Key Points
- CEO Leon Moulder, Jr. bought 60,000 shares of Zenas BioPharma at $16.88 each, spending about $1.01 million. The purchase lifted his direct ownership to 96,928 shares, a 162.48% increase.
- Zenas BioPharma shares traded around $16.91, well below their 50-day average of $21.04 and 200-day average of $26.62. The stock has ranged from a 52-week low of $8.91 to a high of $44.60.
- The company reported a quarterly loss of $1.46 per share, slightly better than analyst expectations of a $1.47 loss. Analysts currently have a mixed view on the stock, with an average rating of Hold and an average target price of $44.29.
Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) CEO Leon Moulder, Jr. purchased 60,000 shares of the business's stock in a transaction dated Monday, May 18th. The stock was bought at an average price of $16.88 per share, with a total value of $1,012,800.00. Following the acquisition, the chief executive officer directly owned 96,928 shares in the company, valued at approximately $1,636,144.64. This represents a 162.48% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Zenas BioPharma Stock Performance
Shares of ZBIO opened at $16.91 on Tuesday. The company has a 50-day simple moving average of $21.04 and a 200-day simple moving average of $26.62. The company has a quick ratio of 11.94, a current ratio of 11.94 and a debt-to-equity ratio of 1.04. The company has a market capitalization of $1.07 billion, a PE ratio of -2.00 and a beta of -0.61. Zenas BioPharma, Inc. has a 52-week low of $8.91 and a 52-week high of $44.60.
Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.47) by $0.01. During the same quarter in the previous year, the company posted ($0.80) earnings per share. Equities research analysts predict that Zenas BioPharma, Inc. will post -4.25 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several research firms recently weighed in on ZBIO. Citigroup reaffirmed a "buy" rating on shares of Zenas BioPharma in a research note on Thursday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Zenas BioPharma in a research note on Friday, March 27th. Wall Street Zen raised Zenas BioPharma from a "strong sell" rating to a "sell" rating in a research note on Saturday. HC Wainwright restated a "buy" rating and set a $44.00 target price on shares of Zenas BioPharma in a report on Friday. Finally, Zacks Research downgraded shares of Zenas BioPharma from a "hold" rating to a "strong sell" rating in a report on Tuesday, March 17th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $44.29.
View Our Latest Research Report on ZBIO
Institutional Investors Weigh In On Zenas BioPharma
A number of hedge funds and other institutional investors have recently modified their holdings of ZBIO. Geode Capital Management LLC grew its holdings in shares of Zenas BioPharma by 4.6% during the second quarter. Geode Capital Management LLC now owns 373,617 shares of the company's stock worth $3,621,000 after buying an additional 16,461 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Zenas BioPharma by 71.3% during the second quarter. Rhumbline Advisers now owns 19,721 shares of the company's stock worth $191,000 after buying an additional 8,207 shares in the last quarter. Sei Investments Co. purchased a new stake in shares of Zenas BioPharma during the second quarter worth about $118,000. Bank of America Corp DE grew its holdings in shares of Zenas BioPharma by 32.3% during the second quarter. Bank of America Corp DE now owns 13,991 shares of the company's stock worth $136,000 after buying an additional 3,412 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Zenas BioPharma by 17.2% during the third quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company's stock worth $25,813,000 after buying an additional 170,546 shares in the last quarter.
Zenas BioPharma Company Profile
(
Get Free Report)
Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company's proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.
Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
